[1] B. Gupta, and N. Kumar, Worldwide incidence, mortality and time trends for cancer of the oesophagus. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 26 (2017) 107-118.
[2] R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA: a cancer journal for clinicians 68 (2018) 7-30.
[3] E.C. Smyth, J. Lagergren, R.C. Fitzgerald, F. Lordick, M.A. Shah, P. Lagergren, and D. Cunningham, Oesophageal cancer. Nature reviews. Disease primers 3 (2017) 17048.
[4] W. Chen, R. Zheng, P.D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X.Q. Yu, and J. He, Cancer statistics in China, 2015. CA: a cancer journal for clinicians 66 (2016) 115-32.
[5] T. Lerut, and O. Wiesel, History of esophagectomy for cancer of the esophagus and the gastroesophageal junction. Annals of translational medicine 9 (2021) 897.
[6] P.S.N. van Rossum, N.H. Mohammad, F.P. Vleggaar, and R. van Hillegersberg, Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends. Nature reviews. Gastroenterology & hepatology 15 (2018) 235-249.
[7] Y. Fu, D. Dominissini, G. Rechavi, and C. He, Gene expression regulation mediated through reversible m⁶A RNA methylation. Nature reviews. Genetics 15 (2014) 293-306.
[8] T. Sun, R. Wu, and L. Ming, The role of m6A RNA methylation in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 112 (2019) 108613.
[9] Q. Lan, P.Y. Liu, J. Haase, J.L. Bell, S. Hüttelmaier, and T. Liu, The Critical Role of RNA m(6)A Methylation in Cancer. Cancer research 79 (2019) 1285-1292.
[10] R. Karthiya, and P. Khandelia, m6A RNA Methylation: Ramifications for Gene Expression and Human Health. Molecular biotechnology 62 (2020) 467-484.
[11] C. Zhang, J. Fu, and Y. Zhou, A Review in Research Progress Concerning m6A Methylation and Immunoregulation. Frontiers in immunology 10 (2019) 922.
[12] Y. Pan, P. Ma, Y. Liu, W. Li, and Y. Shu, Multiple functions of m(6)A RNA methylation in cancer. Journal of hematology & oncology 11 (2018) 48.
[13] L. He, H. Li, A. Wu, Y. Peng, G. Shu, and G. Yin, Functions of N6-methyladenosine and its role in cancer. Molecular cancer 18 (2019) 176.
[14] T. Wang, S. Kong, M. Tao, and S. Ju, The potential role of RNA N6-methyladenosine in Cancer progression. Molecular cancer 19 (2020) 88.
[15] L.C. Xu, J.X. Pan, and H.D. Pan, Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer. Cancer management and research 12 (2020) 5385-5394.
[16] H. Hou, H. Zhao, X. Yu, P. Cong, Y. Zhou, Y. Jiang, and Y. Cheng, METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway. Pathology, research and practice 216 (2020) 153087.
[17] W. Guo, F. Tan, Q. Huai, Z. Wang, F. Shao, G. Zhang, Z. Yang, R. Li, Q. Xue, S. Gao, and J. He, Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Frontiers in immunology 12 (2021) 669750.
[18] T.L. Xia, S.M. Yan, L. Yuan, and M.S. Zeng, Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Cancer management and research 12 (2020) 5729-5737.
[19] H. Guo, B. Wang, K. Xu, L. Nie, Y. Fu, Z. Wang, Q. Wang, S. Wang, and X. Zou, m(6)A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1. Frontiers in oncology 10 (2020) 553045.
[20] M.D. Wilkerson, and D.N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics (Oxford, England) 26 (2010) 1572-3.
[21] Y.C. Yi, X.Y. Chen, J. Zhang, and J.S. Zhu, Novel insights into the interplay between m(6)A modification and noncoding RNAs in cancer. Molecular cancer 19 (2020) 121.
[22] X. Yang, S. Zhang, C. He, P. Xue, L. Zhang, Z. He, L. Zang, B. Feng, J. Sun, and M. Zheng, METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Molecular cancer 19 (2020) 46.
[23] S. Dinescu, S. Ignat, A.D. Lazar, C. Constantin, M. Neagu, and M. Costache, Epitranscriptomic Signatures in lncRNAs and Their Possible Roles in Cancer. Genes 10 (2019).
[24] T. Lan, H. Li, D. Zhang, L. Xu, H. Liu, X. Hao, X. Yan, H. Liao, X. Chen, K. Xie, J. Li, M. Liao, J. Huang, K. Yuan, Y. Zeng, and H. Wu, KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Molecular cancer 18 (2019) 186.
[25] Y. Ban, P. Tan, J. Cai, J. Li, M. Hu, Y. Zhou, Y. Mei, Y. Tan, X. Li, Z. Zeng, W. Xiong, G. Li, X. Li, M. Yi, and B. Xiang, LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma. Molecular oncology 14 (2020) 1282-1296.
[26] F. Pagès, B. Mlecnik, F. Marliot, G. Bindea, F.S. Ou, C. Bifulco, A. Lugli, I. Zlobec, T.T. Rau, M.D. Berger, I.D. Nagtegaal, E. Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, A. Jouret-Mourin, A. Kartheuser, D. Léonard, C. Remue, J.Y. Wang, P. Bavi, M.H.A. Roehrl, P.S. Ohashi, L.T. Nguyen, S. Han, H.L. MacGregor, S. Hafezi-Bakhtiari, B.G. Wouters, G.V. Masucci, E.K. Andersson, E. Zavadova, M. Vocka, J. Spacek, L. Petruzelka, B. Konopasek, P. Dundr, H. Skalova, K. Nemejcova, G. Botti, F. Tatangelo, P. Delrio, G. Ciliberto, M. Maio, L. Laghi, F. Grizzi, T. Fredriksen, B. Buttard, M. Angelova, A. Vasaturo, P. Maby, S.E. Church, H.K. Angell, L. Lafontaine, D. Bruni, C. El Sissy, N. Haicheur, A. Kirilovsky, A. Berger, C. Lagorce, J.P. Meyers, C. Paustian, Z. Feng, C. Ballesteros-Merino, J. Dijkstra, C. van de Water, S. van Lent-van Vliet, N. Knijn, A.M. Mușină, D.V. Scripcariu, B. Popivanova, M. Xu, T. Fujita, S. Hazama, N. Suzuki, H. Nagano, K. Okuno, T. Torigoe, N. Sato, T. Furuhata, I. Takemasa, K. Itoh, P.S. Patel, H.H. Vora, B. Shah, J.B. Patel, K.N. Rajvik, S.J. Pandya, S.N. Shukla, Y. Wang, G. Zhang, Y. Kawakami, F.M. Marincola, P.A. Ascierto, D.J. Sargent, B.A. Fox, and J. Galon, International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet (London, England) 391 (2018) 2128-2139.
[27] Y. Wada, O. Nakashima, R. Kutami, O. Yamamoto, and M. Kojiro, Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology (Baltimore, Md.) 27 (1998) 407-14.
[28] K.I. Al-Shibli, T. Donnem, S. Al-Saad, M. Persson, R.M. Bremnes, and L.T. Busund, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 14 (2008) 5220-7.
[29] Y. Xu, S. Lan, and Q. Zheng, Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. Tumori 104 (2018) 196-201.
[30] N. Shimasaki, A. Jain, and D. Campana, NK cells for cancer immunotherapy. Nature reviews. Drug discovery 19 (2020) 200-218.
[31] S.Y. Wu, T. Fu, Y.Z. Jiang, and Z.M. Shao, Natural killer cells in cancer biology and therapy. Molecular cancer 19 (2020) 120.
[32] E. Montaldo, G. Del Zotto, M. Della Chiesa, M.C. Mingari, A. Moretta, A. De Maria, and L. Moretta, Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry. Part A : the journal of the International Society for Analytical Cytology 83 (2013) 702-13.
[33] K.L. O'Brien, and D.K. Finlay, Immunometabolism and natural killer cell responses. Nature reviews. Immunology 19 (2019) 282-290.
[34] R.S. Mehta, B. Randolph, M. Daher, and K. Rezvani, NK cell therapy for hematologic malignancies. International journal of hematology 107 (2018) 262-270.
[35] E.D. Carosella, N. Rouas-Freiss, D. Tronik-Le Roux, P. Moreau, and J. LeMaoult, HLA-G: An Immune Checkpoint Molecule. Advances in immunology 127 (2015) 33-144.
[36] A. Lin, and W.H. Yan, Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy. Molecular medicine (Cambridge, Mass.) 21 (2015) 782-791.
[37] W.H. Yan, Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer letters 311 (2011) 123-30.
[38] P. Leone, V. De Re, A. Vacca, F. Dammacco, and V. Racanelli, Cancer treatment and the KIR-HLA system: an overview. Clinical and experimental medicine 17 (2017) 419-429.